<p>Drug major Glenmark Pharma on Thursday said it has received final approval from the US health regulator for central nervous system stimulant drug Amphetamine Sulfate tablets.</p>.<p>The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.</p>.<p>Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP in the strengths of 5 mg and 10 mg, it said in a regulatory filing.</p>.<p>Quoting IQVIA sales data for the 12 month period ending November 2020, Glenmark said Evekeo Tablets, 5 mg and 10 mg market achieved annual sales of approximately $21.5 million.</p>.<p>Glenmark's current portfolio consists of 168 products authorised for distribution in the US marketplace and 43 ANDA's pending approval with the USFDA.</p>.<p>Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.</p>
<p>Drug major Glenmark Pharma on Thursday said it has received final approval from the US health regulator for central nervous system stimulant drug Amphetamine Sulfate tablets.</p>.<p>The approved product is a generic version of Evekeo tablets of Arbor Pharmaceuticals LLC.</p>.<p>Glenmark Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for Amphetamine Sulfate tablets USP in the strengths of 5 mg and 10 mg, it said in a regulatory filing.</p>.<p>Quoting IQVIA sales data for the 12 month period ending November 2020, Glenmark said Evekeo Tablets, 5 mg and 10 mg market achieved annual sales of approximately $21.5 million.</p>.<p>Glenmark's current portfolio consists of 168 products authorised for distribution in the US marketplace and 43 ANDA's pending approval with the USFDA.</p>.<p>Shares of Glenmark Pharma were trading 1.44 per cent lower at Rs 478.50 apiece on BSE.</p>